Celcuity Inc.

NASDAQ:CELC

Biotechnology

Healthcare
$55.60 -4.59%

-$4.04 today

Market cap
$2.72B
Beta
0.12
P/E (TTM)
-23.7
EPS (TTM)
-$3.54
52W Low $11.28High $151.02

Volume 0.98M

Average 1.24M

CELC Common Stock Issued

Cash raised by issuing new shares.

Celcuity Inc.NASDAQ: CELC

Common Stock Issued · Q2 FY2026 · quarter ended Jun 2026

Common stock issued grows, but more slowly than its trailing trend

Q2 FY2026 common stock issued of $2.65M rose 870.7% year over year, behind the +1939.0% change in trailing-twelve-month common stock issued. Sequentially, it rose 1018.1% from the prior quarter. Over 3 fiscal years it compounded at +11.1% a year.

Context

  • Common stock issued increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +870.7% toward the trailing-twelve-month pace of +1939.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.65M+1018.1% QoQ
Last fiscal yearDec 2025
$137.85M+116.7% YoY
LTMJun 2026
$119.63M+1939.0% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+870.7%——
1 year+116.7%——
3-year CAGR+11.1%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
137.85M USD
Year-over-year change
+116.7%
4-year CAGR
+15.1%

Common Stock Issued vs competitors

How CELC compares with its peers on the latest reported figures

  • CELC's LTM Jun 2026 common stock issued of $119.63M is the 3rd largest of the 6 companies compared; the peer median is $23.7M.
  • Its year-over-year change of +1939.0% is the highest of 5, against a peer median of +183.1%.
  • Over three fiscal years its annual growth of +11.1% compares with a peer median of -0.4%.
CELC Competitors Peer median
Common Stock Issued for CELC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLLNBillionToOne, Inc.LTM Jun 2026$297.55M ——74.9%
PSNLPersonalis, Inc.LTM Mar 2026$132.59M +16.1%—205.5%
CELCCelcuity Inc.LTM Jun 2026$119.63M +1939.0%+11.1%—
ADPTAdaptive Biotechnologies CorporationLTM Jun 2026$23.7M +227.9%+56.8%7.7%
NEONeoGenomics, Inc.LTM Jun 2026$3.88M +138.2%-57.6%0.5%
CSTLCastle Biosciences, Inc.LTM Mar 2026$2.51M +541.9%—0.7%
Peer median (excluding CELC) $23.7M+183.1%-0.4%7.7%

Competitors are the stored peer set for CELC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(29.61M)(40.37M)(63.78M)(111.78M)(177.04M)
Depreciation & Amortization303.24K210.92K142.77K129.95K167K
Deferred Income Tax00000
Stock-Based Compensation2.61M4.64M4.9M6.99M21.38M
Change in Working Capital819.81K(1.19M)3.86M18.35M(2.65M)
Accounts Receivables(108.76K)95.1K000
Inventory00000
Accounts Payables1.31M1.08M2.43M4.32M(3.04M)
Other Working Capital(377.36K)(2.36M)1.43M14.03M388K
Other Non-Cash Items5.56M704.66K1.06M2.85M4.86M
Operating Cash Flow(20.31M)(36.01M)(53.81M)(83.47M)(153.28M)
Capital Expenditures(81.9K)(158.77K)(97.64K)(249.88K)(249K)
Acquisitions (Net)00000
Purchases of Investments0(143.87M)(314.53M)(705.16M)(396.34M)
Sales of Investments00309.61M642.35M332.51M
Other Investing Activities5000000
Investing Cash Flow(81.4K)(144.03M)(5.01M)(63.07M)(64.08M)
Debt Repayment14.34M19.5M(2.45K)59.23M222.75M
Common Stock Issued78.55M100.5M14.43M63.61M137.85M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities148.02K324.12K50.48M15.55M(46K)
Financing Cash Flow93.04M120.33M64.91M138.39M360.55M
Effect of Forex Changes0000177
Net Change in Cash72.65M(59.71M)6.09M(8.15M)143.19M
Free Cash Flow(20.39M)(36.17M)(53.91M)(83.72M)(153.53M)

Celcuity Inc.

NASDAQ:CELC

Intrinsic Alpha fair value

Locked

Current Price

$55.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.